SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)Â that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices.
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
LOS ANGELES, Aug. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA).
A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.
NEW YORK and NEW ORLEANS, July 31, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NasdaqGM: ADMA) of a class action securities lawsuit.
LOS ANGELES, July 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own headquarters.
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)Â that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices.
